TAMPA, Fla.--(BUSINESS WIRE)--The Moffitt Cancer Center today said findings from a study presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago further validated that VIDAZA (azacitidine) significantly extends overall survival for patients with myelodysplastic syndromes (MDS) compared to conventional care regimens (CCR). Based on this study, investigators have concluded that achieving complete remission is not obligatory for extending survival in higher-risk MDS patients.
